DOSAGE INDEX / SINGLE
Retatrutide
Research, reported schedules and supply planning.
Review retatrutide triple agonism, published diabetes findings, 2026 obesity updates, liver research and the limits behind headline weight-loss claims.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- The source describes distinct weekly trial schedules starting at 2 mg and reaching an assigned target up to 12 mg
- Frequency
- Once weekly
- Cycle / observation period
- Trial-dependent; phase 2 example spans 48 weeks
- Route / research model
- Subcutaneous
Separate trial arms are not one universal escalation plan. Research-vial arithmetic does not establish equivalence to the clinical-trial formulation.
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Compare the product label or clinical-study schedule
338 adults in the 2023 phase 2 obesity trial; BMI at least 30, or at least 27 with a weight-related condition.
Research groups received 1, 4, 8 or 12 mg subcutaneously once weekly over 48 weeks. The 4 mg and 8 mg target groups included starting-dose variants of 2 or 4 mg; the 12 mg group began at 2 mg. These are separate trial arms, not consecutive steps in a universal schedule. The abstract does not supply every intermediate escalation step.
Gastrointestinal adverse effects were dose-related; heart-rate increases also occurred. A lower starting dose partly mitigated gastrointestinal events. This is a historical research description, not a recommended personal regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 5 mg | Enter a total |
| 10 mg | Enter a total |
| 20 mg | Enter a total |
| 30 mg | Enter a total |
| 40 mg | Enter a total |
| 50 mg | Enter a total |
| 60 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- Retatrutide, originally designated LY3437943, is a peptide investigated for activity at GIP, GLP-1 and glucagon receptors. Its discovery study reported stronger GIP-receptor activity than activity at the other two targets in its laboratory assays. In obese mice, the researchers connected reduced food intake and increased energy expenditure with weight reduction. [1]
- In that trial, adverse events led to treatment discontinuation in 2% to 5% of retatrutide participants and none receiving placebo. No severe hypoglycemia was reported. Two deaths occurred in the 4 mg group and were reported as unrelated to the study drug. [2]
- A randomized phase 2a substudy included 98 participants with metabolic dysfunction-associated steatotic liver disease. At week 24, the 12 mg arm had an 82.4% mean relative reduction in liver fat, versus a 0.3% increase with placebo. The investigation used liver-fat measurements and related metabolic assessments. [3]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 112 entries mapped from 7 source pages. Medical and supporting references are retained below; supplier entries are excluded.
- Original discovery research
- Trial safety findings
- Original liver study
- New England Journal of Medicine (2023): Triple-Hormone-Receptor Agonist Retatrutide for Obesity: randomized phase 2 trialFurther reading · Listed in reference bibliography.
- Diabetes, Obesity and Metabolism (2026): TRIUMPH Phase 3 trial design, target doses, and escalationFurther reading · Listed in reference bibliography.
- The Lancet (2023): Retatrutide for type 2 diabetes: randomized phase 2 trialFurther reading · Listed in reference bibliography.
- ClinicalTrials.gov: Phase 2 retatrutide obesity study NCT04881760Trial registry · Listed in reference bibliography.
- Current Obesity Reports (2025): Triple agonism-based therapies for obesityFurther reading · Listed in reference bibliography.
- Nature Reviews Endocrinology (2024): Multi-receptor agonists for metabolic diseaseFurther reading · Listed in reference bibliography.
- Diabetes Care (2024): Incretin-based therapies and cardiovascular considerationsFurther reading · Listed in reference bibliography.
- New England Journal of Medicine (2023): Supplementary material for the phase 2 obesity trialFurther reading · Listed in reference bibliography.
- Hepatology (2024): Triple agonism and hepatic steatosis researchFurther reading · Listed in reference bibliography.
- The Lancet (2023): Supplementary data for the phase 2 diabetes trialFurther reading · Listed in reference bibliography.
- CDC: Subcutaneous administration guidanceGeneral guidance · Listed in reference bibliography.
- Johns Hopkins Arthritis Center: How to give a subcutaneous injectionGeneral guidance · Listed in reference bibliography.
- NCBI Bookshelf: Best practices for injections and related proceduresFurther reading · Listed in reference bibliography.
- Journal of Pharmaceutical Sciences (2018): Stability considerations during freeze-thaw cyclesFurther reading · Listed in reference bibliography.
Product-label / dose evidence
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.